Boehringer Ingelheim R&D pushes to transcend disease boundaries

Promising first-in-class and potential medical breakthrough pipeline projects presented at R&D Press Conference  80 clinical and pre-clinical projects of which 65% have first-in-class and breakthrough potential  Highlight: First-in-class monoclonal antibody shows potential in multiple inflammatory diseases 15 new medicines could

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of empagliflozin in people with chronic kidney disease

University of Oxford to assess effect of empagliflozin on heart and kidney disease in people with chronic kidney disease  EMPA-KIDNEY will be part of the empagliflozin clinical development programme which explores the efficacy and safety of empagliflozin across a broad

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells Assuming all milestones are met, OSE stands to receive more than €1.1 billion 

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine (1)

Results enhance existing evidence base showing Spiolto® Respimat® improves symptom reduction and quality of life over Spiriva® Respimat®2,3,4,5,6  Ingelheim, Germany, 29 March 2018 – Boehringer Ingelheim today announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary